Was about to say something similar. Most drug therapeutics are a reformulation of another drug.
It would simply not make sense for a FDA / EMA to regard two different GLP-1 drugs with different active levels and treatment purposes as the same drug.
IXC has step-changed the value of its portfolio with this development - a portfolio that the market is still significantly under-valuing. And excitingly, pharma M&A is expected to rebound over the next 12-18 months, so IXC's announcement has somewhat fortuitous timing.
IXC Price at posting:
60.0¢ Sentiment: Buy Disclosure: Held
